Right now in Basel: PREFER annual meeting 2019

Today and tomorrow, the PREFER consortium is meeting to discuss the second half of the project and how our patient preference case studies will support the project. We will also talk about how regulatory and HTA qualification and scientific advice for a framework for patient preference studies can help us have impact.

The first day is focused on the feedback of our recent (and successful) mid term review by the Innovative Medicines Initiative (IMI) and the plans for the rest of the project. We will also present initial results and discuss the project's patient preference case studies in workshops.

The second day is devoted to the contents of a briefing book that has just been submitted to EMA, EUnetHTA and NICE, presenting a framework for patient preference studies. We will also discuss patient engagement sand our collaboration with the PARADIGM project, and how to use educational tools for patients in the PREFER case studies.

The meeting is hosted by PREFER partner Roche.

By Josepine Fernow





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).